Prediction of Poor Outcome After Transcatheter Aortic Valve Replacement

详细信息    查看全文

• 作者：Suzanne V. Arnold ; MD ; MHAp>ap>p> ; p>p>bp>p> ; p>p>suz.v.arnold@gmail.com" class="auth_mail" title="E-mail the corresponding authorp> ; Jonathan Afilalo ; MD ; MScp>cp> ; John A. Spertus ; MD ; MPHp>ap>p> ; p>p>bp> ; Yuanyuan Tang ; PhDp>ap> ; Suzanne J. Baron ; MD ; MScp>ap>p> ; p>p>bp> ; Philip G. Jones ; MSp>ap> ; Michael J. Reardon ; MDp>dp> ; Steven J. Yakubov ; MDp>ep> ; David H. Adams ; MDp>fp> ; David J. Cohen ; MD ; MScp>ap>p> ; p>p>bp> ; on behalf of the U.S. CoreValve Investigators
• 关键词：aortic valve stenosis ; frailty ; quality of life ; risk model
• 刊名：Journal of the American College of Cardiology
• 出版年：2016
• 出版时间：25 October 2016
• 年：2016
• 卷：68
• 期：17
• 页码：1868-1877
• 全文大小：748 K

文摘

A series of models have been developed to identify patients at high risk for poor outcomes after transcatheter aortic valve replacement (TAVR) to help guide treatment choices, offer patients realistic expectations of long-term outcomes, and support decision making.p>

Objectives

<p id="abspara0015">This study examined the performance of the previously developed TAVR Poor Outcome risk models in an external dataset and explored the incremental contribution of geriatric domains to model performance.p>

Methods

<p id="abspara0020">Poor outcome after TAVR was defined as death, poor quality of life (QOL), or decline in QOL, as assessed using the Kansas City Cardiomyopathy Questionnaire. We tested 4 TAVR Poor Outcome risk models: 6-month and 1-year full and clinical (reduced) models. We examined each model’s discrimination and calibration in the CoreValve trial dataset, and then tested the incremental contribution of frailty and disability markers to the model’s discrimination using the incremental discrimination index.p>

Results

<p id="abspara0025">Among 2,830 patients who underwent TAVR in the CoreValve US Pivotal Extreme and High Risk trials and associated continued access registries, 31.2% experienced a poor outcome at 6 months following TAVR (death, 17.6%; very poor QOL, 11.6%; QOL decline, 2.0%) and 50.8% experienced a poor outcome at 1 year (death, 30.2%; poor QOL, 19.6%; QOL, decline 1.0%). The models demonstrated similar discrimination as in the Placement of Aortic Transcatheter Valves Trial cohorts (c-indexes, 0.637 to 0.665) and excellent calibration. Adding frailty as a syndrome increased the c-indexes by 0.000 to 0.004 (incremental discrimination index, p < 0.01 for all except the 1-year clinical model), with the most important individual components being disability and unintentional weight loss.p>

Conclusions

<p id="abspara0030">Although discrimination of the TAVR Poor Outcome risk models was generally moderate, calibration was excellent among patients with different risk profiles and treated with a different TAVR device. These findings demonstrated the value of these models for individualizing outcome predictions in high-risk patients undergoing TAVR.